Construction of administration algorithm of novel oral molecular-targeted anti-cancer drugs based on the clarificationof interindividual differences of pharmacokinetics and pharmacodynamics

我们开展了三种新型口服分子靶向抗癌药物的临床药理研究。已证明索拉非尼用于血液透析患者是安全有效的。我们还提供了证据，证明在肠道中表达的乳腺癌耐药蛋白在调节舒尼替尼的药代动力学特征方面起着关键作用。此外，我们报道了厄洛替尼对恶性胸腔积液的非小细胞肺癌患者的疗效和副作用是安全的。这些发现可能为推动新型口服分子靶向抗癌药物的个性化用药提供有用的信息

We carried out clinical pharmacological studies for three kinds of novel oral molecular-targeted anti-cancer drugs. It has been demonstrated that sorafenib can be used safely and effectively for the hemodialyzed patient. We have also provided evidences that Breast Cancer Resistant Protein expressed in the intestine plays pivotal roles for regulatory factors for pharmacokinetic characteristics of sunitinib.Furthermore, we reported that erlotinib can be administered safely to non-small-cell lung cancer patients of malignant pleural effusion with respect to efficacy and side effects. These findings may be useful information to drive the personalized medicine of novel oral molecular-targeted anti-cancer drugs